WEKO3
アイテム
Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
http://hdl.handle.net/10069/23252
http://hdl.handle.net/10069/23252e6fd2916-2b21-40da-9eaf-df9f59236aba
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
公開日 | 2010-07-01 | |||||||||||
タイトル | ||||||||||||
タイトル | Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) | |||||||||||
言語 | ||||||||||||
言語 | eng | |||||||||||
キーワード | ||||||||||||
主題Scheme | Other | |||||||||||
主題 | HAM/TSP | |||||||||||
キーワード | ||||||||||||
主題Scheme | Other | |||||||||||
主題 | HTLV-I | |||||||||||
キーワード | ||||||||||||
主題Scheme | Other | |||||||||||
主題 | Treatment | |||||||||||
資源タイプ | ||||||||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||
資源タイプ | journal article | |||||||||||
著者 |
Nakamura, Tatsufumi
× Nakamura, Tatsufumi
× Nishiura, Yoshihiro
× Eguchi, Katsumi
|
|||||||||||
抄録 | ||||||||||||
内容記述タイプ | Abstract | |||||||||||
内容記述 | Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is chronic progressive myelopathy characterized by bilateral pyramidal tracts involvement with sphincteric disturbances. HTLV-I infects approximately 10-20 million people worldwide. There are large endemic areas in southern Japan, the Caribbean, Central and South America, the Middle East, Melanesia, and equatorial regions of Africa. Since the primary neuropathological feature of HAM/TSP is chronic inflammation caused by HTLV-I infection in the spinal cord, various treatments focusing on immunomodulatory or anti-viral effects were performed for HAM/TSP patients until now. However, there are still many of problems, such as insufficient effects, side effects and expensive costs in long-term treatments, etc., in these treatments. Therefore, an ideal therapeutic strategy against HAM/TSP is still not established yet. Although only a small proportion of HTLV-I-infected individuals develops HAM/TSP, neurological symptoms are certainly progressive once myelopathy develops, leading to deterioration of the quality of life. Therefore, we now need the therapeutic regimens to protect the development, or be able to commence the treatments as soon as possible after the development safely and inexpensively even in long-term course or lifelong course of treatment. As HTLV-I-infected CD4+ T cells are the first responders in the immunopathogenesis of HAM/TSP, the ideal treatment is the elimination of HTLV-I-infected cells from the peripheral blood. In this article, we will review the therapeutic strategies against HAM/TSP up to now and will introduce our new therapeutic approach focusing on the targeting of HTLV-I-infected cells in HAM/TSP patients. | |||||||||||
書誌情報 |
Central Nervous System Agents in Medicinal Chemistry 巻 9, 号 2, p. 137-149, 発行日 2009-06 |
|||||||||||
出版者 | ||||||||||||
出版者 | Bentham Science Publishers | |||||||||||
ISSN | ||||||||||||
収録物識別子タイプ | ISSN | |||||||||||
収録物識別子 | 18715249 | |||||||||||
書誌レコードID | ||||||||||||
収録物識別子タイプ | NCID | |||||||||||
収録物識別子 | AA12127274 | |||||||||||
DOI | ||||||||||||
関連タイプ | isVersionOf | |||||||||||
識別子タイプ | DOI | |||||||||||
関連識別子 | 10.2174/187152409788452090 | |||||||||||
権利 | ||||||||||||
権利情報 | c 2009 Bentham Science Publishers Ltd. | |||||||||||
著者版フラグ | ||||||||||||
出版タイプ | AM | |||||||||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||||
関係URI | ||||||||||||
関連名称 | http://www.bentham.org/cmccnsa/index.htm | |||||||||||
引用 | ||||||||||||
内容記述タイプ | Other | |||||||||||
内容記述 | Central Nervous System Agents in Medicinal Chemistry, 9(2), pp.137-149; 2009 |